OraSure Reports Q3 '24 Revenue of $39.9 Million
Portfolio Pulse from
OraSure Technologies reported Q3 2024 revenue of $39.9 million, with a GAAP EPS of $(0.06) and a Non-GAAP EPS of $(0.01). The company received initial orders for its OraQuick® HCV Self-test after WHO pre-qualification and is expanding into blood proteomics while exiting the risk assessment testing business.
November 06, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OraSure Technologies reported Q3 2024 revenue of $39.9 million, with a GAAP EPS of $(0.06) and a Non-GAAP EPS of $(0.01). The company is focusing on growth by expanding into blood proteomics and exiting the risk assessment testing business.
The revenue and EPS figures indicate a stable financial performance. The WHO pre-qualification for OraQuick® HCV Self-test and expansion into blood proteomics suggest potential growth. Exiting the risk assessment business aligns with focusing on more profitable markets.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100